10-Q: BioCorRx Inc. Q1 2026: Revenue Up, Net Loss Persists

BioCorRx Inc. reported a 59% increase in revenue for Q1 2026, driven by Lucemyra sales, but continued to incur net losses.

Summary

• BioCorRx Inc. reported total net revenues of $214,539 for the three months ended March 31, 2026, a 59% increase compared to $134,899 for the same period in 2025.
• The increase in revenue is primarily attributed to new Lucemyra distribution sales and an increase in sales/access fees.
• Total operating expenses rose to $1,170,539 in Q1 2026 from $1,072,845 in Q1 2025, mainly due to higher research and development costs.
• The company incurred a net loss of $859,892 for Q1 2026, a slight increase from $851,764 in Q1 2025.
• As of March 31, 2026, the company had $211,911 in cash and a working capital deficit of $7,506,752, raising substantial doubt about its ability to continue as a going concern.
• The company is actively seeking additional capital through private placements of debt and equity securities.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the continued net losses, significant working capital deficit raising going concern doubts, and high operating expenses, despite some revenue growth.

Positives

• Revenue increased by 59% to $214,539 in Q1 2026 compared to $134,899 in Q1 2025, driven by Lucemyra distribution sales and increased sales/access fees.
• The company received a significant grant of $11,029,977 from NIDA for research into BICX104 for methamphetamine use disorder.
• The company successfully acquired an additional 12.15% ownership interest in its subsidiary, BioCorRx Pharmaceuticals, Inc.

Negatives

• The company reported a net loss of $859,892 for Q1 2026, continuing its trend of unprofitability.
• A substantial working capital deficit of $7,506,752 as of March 31, 2026, raises substantial doubt about the company's ability to continue as a going concern.
• Total operating expenses increased by $97,694 to $1,170,539 in Q1 2026, primarily due to higher research and development costs.
• The company has a history of net losses since inception.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt due to its recurring net losses and working capital deficit.
• The company's reliance on future capital raises through private placements carries inherent risks regarding availability and adequacy of funding.
• The company faces competition in the substance abuse and weight loss treatment markets.
• Regulatory approvals for drug candidates like BICX104 are subject to uncertainty and can be lengthy and costly processes.
• The company's revenue is highly concentrated, with 99% of revenues in Q1 2026 and 100% in Q1 2025 derived from two customers.

Future Outlook

The company's future outlook is heavily dependent on its ability to secure additional financing to fund its operations and development activities. The company is actively pursuing private placements of debt and equity securities. The success of its drug development pipeline, particularly BICX104 for methamphetamine use disorder, is also critical for future growth.

Management Comments

• The company's financial statements have been prepared in conformity with GAAP, which contemplates continuation as a going concern, but the financial conditions raise substantial doubt.
• The company believes that its current cash on hand will not be sufficient to fund its projected operating requirements for the next twelve months.
• The company will be dependent upon the raising of additional capital through placement of its common stock or by using outside financing.

Industry Context

StockSavvy.ai notes that BioCorRx Inc. operates in the highly competitive and regulated pharmaceutical and healthcare sector, focusing on addiction and weight loss treatments. The company's reliance on grant funding for research and development, particularly for its naltrexone-based therapies, is a common strategy for early-stage biotech firms. The acquisition of Lucemyra assets positions the company to leverage existing FDA-approved products while continuing its R&D efforts.

Comparison to Industry Standards

• The company's revenue growth of 59% in Q1 2026 is a positive sign, but it is crucial to compare this against industry benchmarks for similar-stage pharmaceutical companies. Many early-stage biotech firms experience significant revenue fluctuations tied to R&D milestones and product launches.
• The persistent net loss and negative working capital are common among companies in the clinical-stage drug development phase, where significant investment in R&D is required before substantial revenue generation. Companies like Insys Therapeutics (prior to its issues) and Mallinckrodt Pharmaceuticals have historically navigated similar financial challenges during drug development, though with varying degrees of success and market outcomes.
• The company's dependence on two major customers for nearly all its revenue highlights a concentration risk that is generally viewed negatively compared to more diversified revenue streams seen in larger, established pharmaceutical companies like Pfizer or Johnson & Johnson.

Corporate Governance

Legal Proceedings

• A settlement agreement with Pellecome requires the company to pay $418,000, with $76,500 remaining outstanding as of March 31, 2026.

Related Party Transactions

• Advances from related parties (Kent Emry, Louis C Lucido, Lourdes Felix) totaling $658,263 as of March 31, 2026.
• Interest expense related to these advances and other related party notes payable amounted to $135,448 in Q1 2026.
• Stock exchange agreements with executive officers and Board members to acquire additional ownership in BioCorRx Pharmaceuticals, Inc. in exchange for common stock.

Stakeholder Impact

• Shareholders: Continued net losses and going concern doubts may negatively impact share value. However, revenue growth and R&D progress could be viewed positively.
• Creditors: The company's working capital deficit and reliance on future financing may increase risk for creditors.
• Employees: The company's financial situation could lead to uncertainty regarding job security and future compensation.
• Management: Management is focused on securing funding and advancing R&D, while also managing operational expenses.

Next Steps

• Continue research and development for BICX104, particularly for methamphetamine use disorder.
• Seek additional capital through private placements of debt and equity securities to fund operations and development.
• Continue to leverage the Lucemyra product line through distribution agreements.
• Manage operating expenses, particularly in research and development and selling, general, and administrative costs.

Key Dates

Recommendation

While BioCorRx Inc. shows revenue growth and progress in its R&D pipeline (notably the NIDA grant for BICX104), the persistent net losses, significant working capital deficit, and substantial doubt about its going concern status present considerable risks. The company's ability to secure future financing is paramount. For investors, this situation warrants a 'hold' recommendation, suggesting a cautious approach until there is clearer evidence of financial stability and successful commercialization or significant progress in drug development that de-risks the going concern issue.

Keywords

BioCorRx Inc., Form 10-Q, Quarterly Report, Substance Abuse Treatment, Addiction Treatment, Naltrexone Implant, BICX104, Lucemyra, Revenue Growth, Net Loss, Going Concern, Grant Funding, Pharmaceutical Development